CD6 and T-cell non-Hodgkin lymphoma: Importantly, a CD6-targeted antibody-drug conjugate (anti-CD6-ADC) selectively kills T cell lymphoma cells in vitro and reverses the development of tumors in vivo in mouse models of T cell lymphoma (TCL) (41).